Skip to content

The analgesia mechanism of dexmedetomidine combined with ropivacaine for femoral nerve block in in patients undergoing total knee arthroplasty

Clinical application of dexmedetomidine combined with ropivacaine for femoral nerve block in postoperative analgesia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039348
Enrollment
Unknown
Registered
2020-10-24
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee arthritis

Interventions

Group R:ropivacaine for femora nerve block
Group RD:ropivacaine combined with dexmedetomidine for femora nerve block

Sponsors

The First People's Hospital of Lianyungang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective TKA surgery, preoperative fasting of water for > 12h. 2. American Association of Anesthesiologists (ASA) patient classification I~II. 3. Aged 45~75 years. 4. The patient was informed of the main experimental methods and possible adverse reactions, and signed an informed consent form. 5. The heart, lung, liver, kidney and blood coagulation functions are not abnormal.

Exclusion criteria

Exclusion criteria: 1. History of allergy to related drugs. 2. Patients with severe skin damage and infection lesions in the ultrasound scan area. 3. Patients with severe heart disease and respiratory disease. 4. Those with mental illness or emotional and intellectual disabilities who cannot cooperate.

Design outcomes

Primary

MeasureTime frame
24h total sufentanil consumption;

Secondary

MeasureTime frame
VAS pain score;frequency of PCA pressed;incidence of postoperative nausea and vomiting (PONV);incidence of hypotension and bradycardia;Ramsay assesment;

Countries

China

Contacts

Public ContactLuan Hengfei

The First People's Hospital of Lianyungang

luanhengfei1027@163.com=86 18961325313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026